Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.

Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Dr. Gian Cesare Tron guest at the Oncology Seminar at Nerviano Medical Sciences On Friday,  January 27, at 1:30 PM, Gian Cesare Tron, from the Università degli Studi del Piemonte Orientale, A. Avogadro, Novara, Italy, will give an Oncology Seminar entitled "The search for novel multicomponent reactions: new strategies and molecular scaffolds useful for the medicinal chemist" Gian Cesare Tron received his Degree in Chimica e Tecnologia Farmaceutiche in 1994 at the... Read more
Dr. Andrea Necchi guest at the Oncology Seminar at Nerviano Medical Sciences On Friday January 20th, at 1.30 PM, Dr. Andrea Necchi from the Department of Medicine, Medical Oncology 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan will present an Oncology Seminar entitled “Targeting development of urothelial cancer”. Andre Necchi graduated in Medicine with honors in 2004 at the University of Milan, and he subsequently obtained the specialization in... Read more
Nerviano Medical Sciences announces new License Agreement Nerviano – 15 March, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a license agreement with Novartis.  Under the terms of the agreement, Novartis will receive exclusive rights to an undisclosed family of oncology compounds... Read more
Nerviano Medical Sciences announces a new License Agreement with Genentech for small molecule inhibitors Nerviano – 18 January, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a new license agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY).  This is the third agreement signed between Genentech and... Read more

Oncology

Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet

Read more...

M.I.O.

Nerviano Medical SciencesM.I.O. operates as your partner in the clinical development and life-cycle management

Read more...

Accelera

AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic

Read more...

NerPharMa / DS

NerpharmaNerPharMa and
NerPharMa DS are leading players in high-containment contract

Read more...